DK3426243T3 - 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf - Google Patents
3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf Download PDFInfo
- Publication number
- DK3426243T3 DK3426243T3 DK17764026.5T DK17764026T DK3426243T3 DK 3426243 T3 DK3426243 T3 DK 3426243T3 DK 17764026 T DK17764026 T DK 17764026T DK 3426243 T3 DK3426243 T3 DK 3426243T3
- Authority
- DK
- Denmark
- Prior art keywords
- dehydrogenase inhibitors
- phosphoglycerate dehydrogenase
- phosphoglycerate
- inhibitors
- dehydrogenase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305930P | 2016-03-09 | 2016-03-09 | |
| PCT/US2017/021420 WO2017156165A1 (en) | 2016-03-09 | 2017-03-08 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3426243T3 true DK3426243T3 (da) | 2021-07-19 |
Family
ID=59789738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17764026.5T DK3426243T3 (da) | 2016-03-09 | 2017-03-08 | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10954220B2 (da) |
| EP (2) | EP3426243B1 (da) |
| CY (1) | CY1124338T1 (da) |
| DK (1) | DK3426243T3 (da) |
| ES (2) | ES2965264T3 (da) |
| HR (1) | HRP20211220T1 (da) |
| HU (1) | HUE055197T2 (da) |
| LT (1) | LT3426243T (da) |
| PL (2) | PL3426243T3 (da) |
| PT (1) | PT3426243T (da) |
| RS (1) | RS62271B1 (da) |
| SI (1) | SI3426243T1 (da) |
| WO (1) | WO2017156165A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3426243T3 (pl) | 2016-03-09 | 2021-10-04 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
| EP3426244B1 (en) * | 2016-03-09 | 2023-06-07 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| WO2019074748A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| US11498904B2 (en) | 2017-11-14 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
| KR20230058068A (ko) * | 2020-08-18 | 2023-05-02 | 허치슨 메디파르마 리미티드 | 피리미디논 화합물 및 이의 용도 |
| BR112023023420A2 (pt) | 2021-06-16 | 2024-01-30 | Celgene Corp | Compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativas |
| WO2024132767A1 (en) | 2022-12-19 | 2024-06-27 | Chiesi Farmaceutici S.P.A. | Phosphoglicerate dehydrogenase inhibitors for the treatment of fibrosis |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| MXPA01007099A (es) | 1999-01-13 | 2002-03-27 | Univ New York State Res Found | Metodo novedoso para disenar inhibidores de la proteina cinasa. |
| ES2208433T3 (es) | 1999-12-10 | 2004-06-16 | Pfizer Products Inc. | Compuestos de pirrolo(2,3-d)pirimidina como inhibidores de proteina quinasas. |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP3836436B2 (ja) | 2001-04-27 | 2006-10-25 | 全薬工業株式会社 | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
| AR034897A1 (es) | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
| JP4623962B2 (ja) | 2001-10-22 | 2011-02-02 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ATE419865T1 (de) | 2002-08-14 | 2009-01-15 | Silence Therapeutics Ag | Verwendung von protein-kinase-n-beta |
| JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| ME02688B (me) | 2004-05-13 | 2017-10-20 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta |
| UY29300A1 (es) | 2004-12-22 | 2006-07-31 | Astrazeneca Ab | Compuestos quimicos |
| AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| JP4801096B2 (ja) | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CA2618360C (en) | 2005-08-04 | 2015-06-09 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| BR122021011787B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
| SG10201506912RA (en) | 2005-12-13 | 2015-10-29 | Incyte Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
| HUE025459T2 (hu) | 2006-09-22 | 2016-05-30 | Pharmacyclics Inc | A Bruton-féle tirozin-kináz inhibitorai |
| KR20120049397A (ko) | 2006-11-03 | 2012-05-16 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| MX2009012678A (es) | 2007-05-25 | 2012-09-20 | Vertex Pharma | Moduladores de canal de ion y metodos de uso. |
| SG191660A1 (en) | 2008-03-11 | 2013-07-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| MX2011004625A (es) * | 2008-11-03 | 2011-07-20 | Syntarga Bv | Analogos cc-1065 novedosos y sus conjugados. |
| US9096579B2 (en) * | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| UA121386C2 (uk) * | 2014-04-04 | 2020-05-25 | Айомет Фарма Лтд | Похідні індолу, фармацевтична композиція, яка їх містить, та способи їх застосування |
| EP3426244B1 (en) | 2016-03-09 | 2023-06-07 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| PL3426243T3 (pl) | 2016-03-09 | 2021-10-04 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
-
2017
- 2017-03-08 PL PL17764026T patent/PL3426243T3/pl unknown
- 2017-03-08 HU HUE17764026A patent/HUE055197T2/hu unknown
- 2017-03-08 SI SI201730882T patent/SI3426243T1/sl unknown
- 2017-03-08 LT LTEP17764026.5T patent/LT3426243T/lt unknown
- 2017-03-08 PL PL21167434.6T patent/PL3884939T3/pl unknown
- 2017-03-08 PT PT177640265T patent/PT3426243T/pt unknown
- 2017-03-08 WO PCT/US2017/021420 patent/WO2017156165A1/en active Application Filing
- 2017-03-08 ES ES21167434T patent/ES2965264T3/es active Active
- 2017-03-08 ES ES17764026T patent/ES2883328T3/es active Active
- 2017-03-08 EP EP17764026.5A patent/EP3426243B1/en active Active
- 2017-03-08 US US16/082,659 patent/US10954220B2/en active Active
- 2017-03-08 DK DK17764026.5T patent/DK3426243T3/da active
- 2017-03-08 RS RS20211023A patent/RS62271B1/sr unknown
- 2017-03-08 EP EP21167434.6A patent/EP3884939B1/en active Active
-
2021
- 2021-01-15 US US17/150,669 patent/US11634412B2/en active Active
- 2021-07-19 CY CY20211100651T patent/CY1124338T1/el unknown
- 2021-07-28 HR HRP20211220TT patent/HRP20211220T1/hr unknown
-
2023
- 2023-03-01 US US18/115,942 patent/US20230312536A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2965264T3 (es) | 2024-04-11 |
| HRP20211220T1 (hr) | 2021-10-29 |
| RS62271B1 (sr) | 2021-09-30 |
| EP3426243B1 (en) | 2021-05-19 |
| PL3426243T3 (pl) | 2021-10-04 |
| CY1124338T1 (el) | 2022-07-22 |
| US20230009122A1 (en) | 2023-01-12 |
| US11634412B2 (en) | 2023-04-25 |
| US20230312536A1 (en) | 2023-10-05 |
| PL3884939T3 (pl) | 2024-02-26 |
| EP3884939A1 (en) | 2021-09-29 |
| PT3426243T (pt) | 2021-08-19 |
| EP3884939C0 (en) | 2023-10-25 |
| WO2017156165A1 (en) | 2017-09-14 |
| EP3426243A4 (en) | 2019-07-03 |
| SI3426243T1 (sl) | 2021-11-30 |
| US10954220B2 (en) | 2021-03-23 |
| HUE055197T2 (hu) | 2021-11-29 |
| ES2883328T3 (es) | 2021-12-07 |
| LT3426243T (lt) | 2021-08-10 |
| EP3426243A1 (en) | 2019-01-16 |
| EP3884939B1 (en) | 2023-10-25 |
| US20190071431A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3521289T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3426243T3 (da) | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
| DK3621694T5 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3256598T3 (da) | Svampestammer og anvendelsesfremgangsmåder | |
| DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
| EP3426244C0 (en) | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND THEIR USES | |
| DK3280405T3 (da) | Inhibitorer og anvendelser deraf | |
| DK3142659T3 (da) | Hiv-1 proteasehæmmere og anvendelser deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
| DK3240821T3 (da) | Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde |